Copyright
©The Author(s) 2020.
World J Diabetes. Apr 15, 2020; 11(4): 137-149
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.137
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.137
Trial | Drug (daily doses, mg) | |
Clopidogrel + Aspirin | Aspirin | |
CHANCE 2013 | Clopidogrel (day 1: 300; day 2-90: 75) + Aspirin (day 1: 75-300; day 2-21: 75; day 22-90: placebo) | Aspirin (day 1: 75-300; day 2-90: 75) |
CHARISM 2006 | Clopidogrel (75) + Aspirin (75-162) | Aspirin (75-162) |
CREDO 2002 | Clopidogrel (day 1: 300; day 2 to 12 mo: 75) + Aspirin (day 1: 325; day 2 to 12 mo: 81-325) | Clopidogrel (day 2-28: 75) + Aspirin (day 1: 325; day 2 to 12 mo: 81-325) |
CURE 2001 | Clopidogrel (day 1: 300, and then 75) + Aspirin (75-325) | Aspirin (75-325) |
POINT 2018 | Clopidogrel (day 1: 600, and then 75) + Aspirin (50-325) | Aspirin (50-325) |
SPS3 2012 | Clopidogrel (75) + Aspirin (325) | Aspirin (325) |
- Citation: Liang LR, Ma Q, Feng L, Qiu Q, Zheng W, Xie WX. Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. World J Diabetes 2020; 11(4): 137-149
- URL: https://www.wjgnet.com/1948-9358/full/v11/i4/137.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i4.137